A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years

OBJECTIVE: To assess the safety and efficacy of the endothelin receptor antagonist ambrisentan in pediatric pulmonary arterial hypertension (PAH). STUDY DESIGN: In this open-label, phase IIb study, patients with PAH aged 8 to <18 years were randomized to low- or high-dose ambrisentan for 24 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivy, Dunbar, Beghetti, Maurice, Juaneda-Simian, Ernesto, Miller, Diane, Lukas, Mary Ann, Ioannou, Chris, Okour, Malek, Narita, Jun, Berger, Rolf M.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236545/
https://www.ncbi.nlm.nih.gov/pubmed/37332660
http://dx.doi.org/10.1016/j.ympdx.2020.100055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236545/
https://www.ncbi.nlm.nih.gov/pubmed/37332660
http://dx.doi.org/10.1016/j.ympdx.2020.100055

Ejemplares similares